# GSK

> GSK is a London-headquartered global biopharma company that discovers, develops, manufactures and sells vaccines, specialty medicines and general medicines. Its portfolio spans shingles, RSV, meningitis, HIV, asthma and COPD, lupus, cancer and bacterial infections, while its R&D strategy concentrates on immune science, human genetics and advanced technologies. After separating consumer health company Haleon in 2022, GSK became a more focused prescription medicines and vaccines business serving patients through healthcare professionals, health systems, pharmacies, governments and international procurement organisations in roughly 70 markets.

- **Founded:** 2000
- **Headquarters:** London, United Kingdom
- **Team size:** 66,800 employees at 31 December 2025
- **Products:** Shingrix, Arexvy, Bexsero, Trelegy Ellipta, Nucala
- **Notable:** Reported £32.7 billion of group turnover in 2025, including £13.5 billion from Specialty Medicines and £9.2 billion from Vaccines., Supplied more than 2 billion packs of medicine and vaccine doses in 2025., Delivered 99 million doses of critical vaccines to Gavi in 2025 for use in lower-income countries.

## Products & services

- **Shingrix** — Recombinant, adjuvanted vaccine for the prevention of shingles.
- **Arexvy** — Adjuvanted vaccine for prevention of lower respiratory tract disease caused by RSV in eligible adults.
- **Bexsero** — Vaccine against meningococcal group B disease.
- **Trelegy Ellipta** — Once-daily triple inhaled therapy used in COPD and, in some markets, asthma.
- **Nucala** — Mepolizumab biologic for severe eosinophilic asthma and other eosinophil-driven conditions.
- **Benlysta** — Belimumab specialty medicine for systemic lupus erythematosus and lupus nephritis.
- **Dovato** — Two-drug, once-daily HIV treatment from majority-owned ViiV Healthcare.
- **Cabenuva / Vocabria plus Rekambys** — Long-acting injectable HIV treatment regimen, marketed under regional brand names.
- **Jemperli** — Dostarlimab immunotherapy used in selected cancers, including endometrial cancer.
- **Blenrep** — Antibody-drug conjugate for eligible patients with relapsed or refractory multiple myeloma, with availability varying by market and indication.
- **Blujepa** — Gepotidacin oral antibiotic for uncomplicated urinary tract infection, representing a new antibiotic class.
- **Penmenvy** — Five-in-one meningococcal vaccine covering groups A, B, C, W and Y.

## Achievements

- Reported £32.7 billion of group turnover in 2025, including £13.5 billion from Specialty Medicines and £9.2 billion from Vaccines.
- Supplied more than 2 billion packs of medicine and vaccine doses in 2025.
- Delivered 99 million doses of critical vaccines to Gavi in 2025 for use in lower-income countries.
- Maintained a pipeline of 58 medicines and vaccines, including 17 assets in phase III or registration at year-end 2025.
- Received five major product approvals and started seven pivotal trials in 2025.
- Ranked second among 20 large pharmaceutical companies in the 2024 Access to Medicine Index.
- Completed the separation of consumer-health business Haleon in 2022, creating a focused biopharma company.
- Completed the $10.6 billion acquisition of Nuvalent in July 2026, adding three precision lung-cancer assets.

## Latest updates

- **2026-07** — The US FDA approved Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer.
- **2026-07** — GSK completed its approximately $10.6 billion acquisition of Nuvalent, adding three precision lung-cancer assets.
- **2026-07** — The European Medicines Agency accepted a submission to update the Bexsero label for a one-dose meningitis B booster in people aged 10 and older.
- **2026-05** — Japan expanded approval of RSV vaccine Arexvy to adults aged 18 to 59 who are at increased risk.
- **2026-04** — Bepirovirsen received US FDA priority review and Breakthrough Therapy Designation as an investigational treatment for chronic hepatitis B.
- **2026-04** — GSK completed its acquisition of 35Pharma, adding the late-stage activin E trap efimosfermin to its liver-disease pipeline.
- **2026-03** — The US FDA approved Lynavoy (linerixibat) for cholestatic pruritus in primary biliary cholangitis.
- **2026-03** — GSK completed its acquisition of RAPT Therapeutics, strengthening its immunology and inflammation pipeline.

## Links

- Website: https://www.gsk.com/
- LinkedIn: https://www.linkedin.com/company/gsk
- Twitter/X: https://twitter.com/GSK
- YouTube: https://www.youtube.com/user/gskvision
- Bluesky: https://bsky.app/profile/gsk.bsky.social
- Instagram: https://www.instagram.com/gsk/
- Facebook: https://www.facebook.com/GSK

---

Profile page: https://yespress.io/gsk
Published by YesPress — https://yespress.io
Last updated: 2026-08-12